This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
calcium-channel-blockers
Calcium Channel Blockers
Block voltage-gated L-type calcium channels. Two subclasses: dihydropyridines (vasodilation-predominant; e.g. amlodipine) and non-dihydropyridines (cardiac rate/conduction; e.g. verapamil, diltiazem). First-line for hypertension and angina.
Entry Metadata
| Field | Value |
|---|---|
| ID | calcium-channel-blockers |
| Name | Calcium Channel Blockers |
| Status | draft |
| Last reviewed | 2026-06-04 |
| Stream | 01-modern |
| Drug class | calcium channel antagonist |
Cross-Atlas Connections
Sources
- ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288(23):2981-97.
- Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. N Engl J Med. 2004;350(23):2352-8.
- Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355(9207):865-72. · PubMed 11289345
- Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-31. · PubMed 15207952